Advertisement
The FDA approved the drug for breast cancer late on Friday, Feb. 23 andsurprised many in the industry since the FDA advisory committee had votedagainst the approval in December. An August 2007 survey by Decision Resourcesfound that a very high rate of oncologists prescribing Avastin off-label totreat metastatic breast cancer. In August of 2007, 79 percent of U.S.oncologists were using Avastin to treat breast cancer patients. Thisprescribing behavior is driven by familiarity with Avastin for colorectalcancer and non-small-cell lung cancer, and by the E2100 trial data presentedat ASCO.
Advertisement
For those reporters covering this topic, Mr. Muhsin is available forquestions regarding Avastin and its use in the breast cancer market including:
To speak with Mr. Muhsin, please contact Liz Marshall at 781-296-2563 [email protected].
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com) is a worldleader in market research publications, advisory services, and consultingdesigned to help clients shape strategy, allocate resources, and master theirchosen markets.
All company, brand, or product names contained in this document may betrademarks or registered trademarks of their respective holders.-- What impact will the approval have on the breast cancer drug market? -- What impact will the approval have on Avastin? -- Will Avastin achieve record-breaking revenues? -- How will the uptake by insurers and Medicare progress now that Avastin is approved for breast cancer? -- What lessons can be learned from the FDA's reaction to the E2100 trial? -- What does Avastin's approval for breast cancer mean for other cancer drugs in line for approval by the FDA?
SOURCE Decision Resources
